BR100 Increased By (0.52%)
BR30 Increased By (0.44%)
KSE100 Increased By (0.46%)
KSE30 Increased By (0.58%)
BECO 5.67 Decreased By ▼ -0.06 (-1.05%)
BML 57.05 Decreased By ▼ -0.25 (-0.44%)
BOP 36.85 Increased By ▲ 0.08 (0.22%)
CNERGY 8.32 Decreased By ▼ -0.07 (-0.83%)
DCL 11.90 Decreased By ▼ -0.14 (-1.16%)
FCCL 58.66 Increased By ▲ 0.05 (0.09%)
FCSC 5.09 Increased By ▲ 0.08 (1.6%)
FFL 18.12 Increased By ▲ 0.18 (1%)
FNEL 1.26 No Change ▼ 0.00 (0%)
HUMNL 11.28 Decreased By ▼ -0.14 (-1.23%)
KEL 8.24 Decreased By ▼ -0.05 (-0.6%)
KOSM 6.54 Decreased By ▼ -0.08 (-1.21%)
MLCF 107.17 Decreased By ▼ -1.12 (-1.03%)
NBP 208.80 Increased By ▲ 2.76 (1.34%)
PACE 11.18 Increased By ▲ 0.01 (0.09%)
PAEL 45.39 Increased By ▲ 0.04 (0.09%)
PIAHCLA 30.31 Decreased By ▼ -0.46 (-1.49%)
PIBTL 18.87 Decreased By ▼ -0.19 (-1%)
PPL 248.71 Increased By ▲ 2.76 (1.12%)
PRL 36.29 Increased By ▲ 0.21 (0.58%)
PTC 74.01 Increased By ▲ 1.65 (2.28%)
SEARL 96.13 Decreased By ▼ -0.54 (-0.56%)
SSGC 31.37 Decreased By ▼ -0.30 (-0.95%)
TELE 9.21 Decreased By ▼ -0.06 (-0.65%)
THCCL 68.04 Increased By ▲ 0.23 (0.34%)
TPLP 11.64 Increased By ▲ 0.41 (3.65%)
TREET 25.72 Decreased By ▼ -0.17 (-0.66%)
TRG 67.62 Decreased By ▼ -0.22 (-0.32%)
WAVES 11.25 Increased By ▲ 0.27 (2.46%)
WTL 1.28 No Change ▼ 0.00 (0%)

ISLAMABAD: The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) and the Federal Board of Revenue (FBR) on Wednesday discussed the issues related to the sales tax regime governing the pharma sector.

A delegation of the PPMA called upon the FBR Chairman, Asim Ahmad, at the FBR HQs.

The delegation was led by PPMA Chairman Syed Farooq Bukhari and included the PPMA members as well as ex-chairman of the Association. The meeting was also attended by Member IR-Policy FBR Afaq Ahmad Qureshi.

The delegation discussed the issues related to the sales tax regime governing the pharma sector and invited the FBR chairman to attend the pharma export seminar. Several other operational issues were also discussed during the meeting.

Copyright Business Recorder, 2023

Comments

Comments are closed for this article.